UNSPSC 51422320: Halometasone

This classification denotes a betamethasone analog, anti-asthmatic agent, anti-inflammatory agent, and glucocorticoid with the molecular formula C22H27ClF2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J69Z9UU41Z, chemically known as 2-chloro-6alpha,9-difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione but generally known as halometasone, which bears US NIH Compound Identifier 39745.

UNSPSC 51422320 Halometasone (Commodity) encompasses pharmaceutical products and preparations that state and local health agencies procure to support community health and emergency response initiatives. Recent state and local solicitations under this code show a significant mismatch between the nominal product — halometasone, a topical corticosteroid — and the actual goods being purchased. The Seminole County, Florida IFB solicits naloxone and drug deactivation systems for opioid response and harm reduction; the Texas Health and Human Services Commission RFI explores direct-to-manufacturer prescription fulfillment models more broadly. The code designation appears misaligned with the work actually being bought. State and local issuing bodies pursuing pharmaceutical procurement span county health departments, state health commissions, and local community health agencies. Issuing bodies vary in their approach — Seminole County uses competitive sealed bidding (IFB) for recurring supply procurement, while the Texas HHS Commission employs RFI mechanisms to gather market intelligence before formal competitive solicitation. Vendors responding to these opportunities must meet standard compliance requirements including drug-free workplace certification, E-Verify eligibility verification, and applicable insurance coverage; FEMA-funded procurements introduce additional federal regulatory compliance obligations.

Geographic activity in pharmaceutical procurement under this code spans Florida and Texas. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; vendors must include all shipping and delivery costs in their proposals. The Texas HHS Commission RFI (HHS0017013, posted April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription contracting without traditional pharmacy benefit manager intermediation. The code shows limited recent activity clearly aligned with halometasone procurement; business development professionals evaluating this Commodity code should focus on the broader pharmaceutical supply and pharmacy benefits management market rather than the specific corticosteroid product the code nominally identifies.